Xvivo Perfusion AB (XVIVO) - Total Liabilities
Based on the latest financial reports, Xvivo Perfusion AB (XVIVO) has total liabilities worth Skr299.60 Million SEK (≈ $32.24 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Xvivo Perfusion AB equity growth rate to track the company's year-over-year net asset growth rate.
Xvivo Perfusion AB - Total Liabilities Trend (2011–2025)
This chart illustrates how Xvivo Perfusion AB's total liabilities have evolved over time, based on quarterly financial data. See XVIVO free cash flow to operating cash ratio to measure how efficiently the company converts operating cash flow to free cash.
Xvivo Perfusion AB Competitors by Total Liabilities
The table below lists competitors of Xvivo Perfusion AB ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
IRB-Brasil Resseguros S.A.
SA:IRBR3
|
Brazil | R$10.13 Billion |
|
Domino's Pizza Enterprises Limited
F:HQX
|
Germany | €2.01 Billion |
|
Beijing Oriental Jicheng Co Ltd
SHE:002819
|
China | CN¥1.51 Billion |
|
Cullinan Oncology LLC
NASDAQ:CGEM
|
USA | $36.81 Million |
|
Hna-Caissa Travel Group Co Ltd
SHE:000796
|
China | CN¥885.87 Million |
|
Elevra Lithium Limited
AU:ELV
|
Australia | AU$205.99 Million |
|
Guangzhou Hengyun Enterprises Holding Ltd
SHE:000531
|
China | CN¥10.75 Billion |
Liability Composition Analysis (2011–2025)
This chart breaks down Xvivo Perfusion AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see how much is Xvivo Perfusion AB worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.52 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.14 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.12 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Xvivo Perfusion AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Xvivo Perfusion AB (2011–2025)
The table below shows the annual total liabilities of Xvivo Perfusion AB from 2011 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | Skr260.65 Million ≈ $28.05 Million |
+5.97% |
| 2024-12-31 | Skr245.97 Million ≈ $26.47 Million |
-1.84% |
| 2023-12-31 | Skr250.57 Million ≈ $26.96 Million |
-17.29% |
| 2022-12-31 | Skr302.95 Million ≈ $32.60 Million |
+17.81% |
| 2021-12-31 | Skr257.15 Million ≈ $27.67 Million |
+81.28% |
| 2020-12-31 | Skr141.85 Million ≈ $15.27 Million |
+149.00% |
| 2019-12-31 | Skr56.97 Million ≈ $6.13 Million |
+23.48% |
| 2018-12-31 | Skr46.13 Million ≈ $4.96 Million |
+34.87% |
| 2017-12-31 | Skr34.21 Million ≈ $3.68 Million |
+4.03% |
| 2016-12-31 | Skr32.88 Million ≈ $3.54 Million |
+70.33% |
| 2015-12-31 | Skr19.31 Million ≈ $2.08 Million |
-24.34% |
| 2014-12-31 | Skr25.52 Million ≈ $2.75 Million |
-17.50% |
| 2013-12-31 | Skr30.93 Million ≈ $3.33 Million |
+20.10% |
| 2012-12-31 | Skr25.75 Million ≈ $2.77 Million |
-80.03% |
| 2011-12-31 | Skr128.97 Million ≈ $13.88 Million |
-- |
About Xvivo Perfusion AB
Xvivo Perfusion AB (publ), a medical technology company, develops and markets machines and perfusion solutions for assessing usable organs and maintains in optimal condition pending transplantation in Sweden. It operates through Thoracic; Abdominal; Services; and other segments. The company offers Kidney Assist Transport, a portable device that allows hypothermic pulsatile perfusion of donor kidn… Read more